论文部分内容阅读
胆道系统恶性肿瘤是一种发病率低、预后差的肿瘤,包括胆管癌、胆囊癌及壶腹部癌。在西方国家胆道系统恶性肿瘤大约占胃肠道肿瘤的4%,东南亚发病率相对较高。在我国,胆道系统恶性肿瘤的发病率并没有明确数字,约占消化道肿瘤的第6位。胆系肿瘤生存率低,预后差,至今尚无有效的化疗方案。目前,关于进展期胆系肿瘤化疗的Ⅱ、Ⅲ期临床试验研究以逐渐开展,化疗方案以吉西他滨为主,单药或联合铂类等药物,得到了明显提高的有效率及生存期。本文就目前胆系肿瘤化疗方面新的进展及成果做综述。
Biliary system malignancy is a low incidence, poor prognosis of the tumor, including cholangiocarcinoma, gallbladder cancer and ampullary cancer. In western countries, biliary system malignant tumors account for about 4% of gastrointestinal tumors, the incidence of relatively high in Southeast Asia. In our country, the incidence of malignant biliary tract cancer is not clear figures, accounting for about 6 of gastrointestinal tumors. Biliary tumor survival rate is low, the prognosis is poor, so far no effective chemotherapy. At present, the progress of phase Ⅱ and Ⅲ clinical trials of chemotherapy for advanced gallbladder tumors has been gradually carried out. Chemotherapy programs mainly include gemcitabine, and single or combined platinum drugs have significantly improved the efficiency and survival. This article summarizes the recent progress and achievements in gallbladder tumor chemotherapy.